Formestane
Appearance
Clinical data | |
---|---|
Other names | 4-hydroxyandrost-4-ene-3,17-dione |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.153.838 |
Chemical and physical data | |
Formula | C19H26O3 |
Molar mass | 302.408 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Formestane belongs to a class of drugs known as 2 aromatase inhibitors. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection (Lentaron).
Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor.
Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified.
It is selective.[1]
References
- ^ Pérez Carrión R, Alberola Candel V, Calabresi F; et al. (1994). "Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer". Ann. Oncol. 5 Suppl 7: S19–24. PMID 7873457.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link)